Scott L. Klakamp
17Patents
8h-index
56Co-inventors
75Inventor score
Filing activity: Mar 7, 1995 → Nov 4, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5714166A | Bioactive and/or targeted dendrimer conjugates | Emerging Cross-Sectional Technologies | 228 | Expired |
| US7285269B2 | Antibodies directed to tumor necrosis factor | Chemistry; Metallurgy | 68 | Expired |
| US7628986B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 60 | Expired |
| US7566772B2 | Antibodies against interleukin-1β | Emerging Cross-Sectional Technologies | 42 | Expired |
| US7736644B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 33 | Expired |
| US7585500B2 | Fully human monoclonal antibodies to IL-13 | Chemistry; Metallurgy | 16 | Active |
| US9096672B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 13 | Active |
| US7964193B2 | Antibodies against interleukin-1 β | Emerging Cross-Sectional Technologies | 12 | Active |
| US7994302B2 | Fully human monoclonal antibodies to IL-13 | Chemistry; Metallurgy | 8 | Active |
| US9062113B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 6 | Active |
| US8846873B2 | Antibodies directed to GPNMB and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US9073998B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US10118968B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US9085624B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 2 | Active |
| US8101178B2 | Antibodies directed to tumor necrosis factor and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US10508153B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US11492411B2 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.